Parkinsons Therapy Lead Casma's lead program CSM-101 targets Parkinsons disease and Gaucher disease with an oral disease-modifying potential; MJFF awarded funding in 2026, signaling external validation and a potential pathway for co-development deals with PD/Gaucher assets; BD teams should target partnerships to co-develop or license into these indications.

PHLYTTM Platform Value PHLYTTM degrader platform enables selective autophagy-targeted degradation of large targets like organelles and protein aggregates, offering pharma partners a route to address previously intractable targets. Licensing or collaboration could accelerate discovery programs across neurodegeneration, oncology, inflammation, and metabolic diseases.

Funding & Validation A strong early funding trajectory including a high-visibility Series A in 2023 and ongoing grant support from The Michael J. Fox Foundation signals credibility for co-development partnerships and risk-sharing deals; Casma's active presence at industry events indicates readiness for BD engagement.

Strategic Location Based in Cambridge, Massachusetts, Casma sits in a dense biopharma ecosystem that facilitates access to potential collaborators, CROs, manufacturers, and talent; active BD outreach is evidenced by participation in Needham and Targeted Protein Degradation Day events.

Indication Expansion Casma's broad disease focus neurodegeneration, oncology, inflammation, and metabolic disorders offers multi-indication partnership potential; opportunities include licensing CSM-101 and PHLYTTM for PD, Gaucher, and related neurodegenerative diseases, accelerating portfolio breadth.